Salute e Benessere
Multi Cancer Early Detection Testing Market to Reach US$ 7.52 Billion by 2033 as Galleri, CancerSEEK, and Next-Gen Liquid Biopsies Lead Global Adoption
Global adoption is accelerating, led by Investments from Roche's Foundation Medicine and biotech innovators such as Burning Rock, Lucence Health, and Freenome are further shaping the competitive landscape.
Its ability to detect over 50 types of cancers with high specificity has made it the benchmark in MCED adoption across the U.S. and Europe .
The test is expanding rapidly in colorectal, ovarian, and lung cancer detection.
supported by early detection programs in the U.S. and
Japan .
as liquid biopsy solutions gain traction over invasive colonoscopies and imaging scans.
are benefiting from MCED's non-invasive detection advantages.
reflecting their role as the primary hubs for early cancer diagnosis.
with large lab chains partnering with biotech firms to expand access.
remain critical for clinical validation, biomarker discovery, and regulatory pathway advancement.
The U.S. leads the MCED market with revenues exceeding Growth is fueled by:
Japan's MCED market, valued at is gaining momentum due to:
GRAIL leads the MCED space with its currently the most widely validated early detection test. Backed by Illumina and industry partnerships, GRAIL is expanding across North America , Europe , and Asia .
Guardant has established itself as a leveraging genomic sequencing to detect early-stage cancers. In 2025, the company enhanced its MCED portfolio with AI-powered detection of gastrointestinal cancers.
Known for its Exact Sciences is expanding into MCED through partnerships with research institutes. Its are positioned to capture share in colorectal and pancreatic cancers.
These companies are driving innovation in Asia , focusing on cost-effective, scalable MCED solutions. Their tests are gaining regulatory traction in Japan and China .
Foundation Medicine brings strong diagnostic credibility, with 2025 developments focused on integrating MCED into comprehensive genomic profiling solutions.
The MCED market is at a pivotal stage of evolution. Four themes define its future trajectory:
The is redefining global cancer care. With leading the innovation curve, MCED is positioned to transform survival outcomes by shifting cancer detection from late-stage diagnosis to early intervention.
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com or follow us on Twitter, LinkedIn and Facebook.
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/multi-cancer-early-detection-testing-market-to-reach-us-7-52-billion-by-2033-as-galleri-cancerseek-and-next-gen-liquid-biopsies-lead-global-adoption-302577088.html